All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the EHA 2022 Congress, the Lymphoma Hub spoke with Marek Trněný, Charles University, Prague, CZ. We asked, Is peripheral neuropathy in patients with diffuse large B-cell lymphoma (DLBCL) more severe after pola-R-CHP vs R-CHOP treatment?
Is peripheral neuropathy in patients with DLBCL more severe after pola-R-CHP vs R-CHOP treatment?
Trněný begins by outlining the POLARIX study, which showed significant improvement in progression-free survival (PFS) for patients treated with pola-R-CHP vs R-CHOP. Trněný highlights findings on the toxicity profile, and underlines the need for increased research into the effect that peripheral neuropathy has on quality of life. Also, Trněný discusses the findings of his study, including incidence and duration of peripheral neuropathy in both treatment arms.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Educational theme: High-risk patients with lymphoid malignancies
Despite the plethora of regimens and the chemosensitivity of aggressive B-cell lymphomas, many patients fail to respond well to treatment. This article collates expert opinions...
Prof. Marek Trneny | EBMT 2018 | What were the most interesting results from EBMT?
What were the most interesting results from EBMT?
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox